Share This Page
Drugs in MeSH Category Membrane Transport Modulators
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leo Pharm | PINDAC | pinacidil | CAPSULE, EXTENDED RELEASE;ORAL | 019456-001 | Dec 28, 1989 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Leo Pharm | PINDAC | pinacidil | CAPSULE, EXTENDED RELEASE;ORAL | 019456-002 | Dec 28, 1989 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Membrane Transport Modulators
Market Overview
Membrane transport modulators influence the movement of ions, nutrients, or drugs across cellular membranes. These drugs are used in various therapeutic areas, including neurological disorders, cancer, and infectious diseases. The global market is driven by increasing demand for targeted therapies and advancements in precision medicine.
Key market segments include ion channel modulators, transporter inhibitors, and regulatory protein modulators. The ion channel subgroup predominates in revenue, particularly drugs targeting calcium, sodium, and potassium channels used in cardiovascular and neurological indications.
Projected market size for this class reached approximately $15 billion in 2022, with a compound annual growth rate (CAGR) forecasted at 6% through 2030 (source: MarketsandMarkets [1]). Growth drivers include rising prevalence of neurological conditions such as epilepsy and multiple sclerosis, alongside an aging population demanding more effective treatments.
Therapeutic Areas
- Neurological disorders: Antiepileptic drugs, multiple sclerosis, neuropathic pain.
- Oncology: Transporter inhibitors impacting drug resistance and tumor microenvironment.
- Cardiovascular: Calcium channel blockers, sodium channel modulators.
- Infectious diseases: Transporter-targeted antimicrobials.
Recent trends show increased investment in ion channel modulators for psychiatric and neurodegenerative disorders, as well as novel transporter inhibitors targeting cancer cells for overcoming multidrug resistance.
Patent Landscape
The patent landscape in this domain is characterized by a high density of filings concentrated in North America, Europe, and Asia. Major pharmaceutical companies and biotech firms pursue patents on new chemical entities, formulations, method-of-use claims, and delivery systems.
Patent Filing Trends
- Annual filings: Consistently increase, with peaks in 2015, 2018, and 2021, reflecting R&D activity upticks.
- Major jurisdictions: United States (US), European Patent Office (EPO), China State Intellectual Property Office (SIPO).
- Leading assignees: Novartis, Merck & Co., Boehringer Ingelheim, and AbbVie dominate patent filings, particularly in sodium and calcium channel modulators.
Patent Types & Strategies
- Composition of matter claims: Cover novel chemical entities with specific ion channel or transporter activity.
- Use claims: Covering new therapeutic indications or combination therapies.
- Formulation patents: Extended IP protection through novel delivery systems or formulations.
- Method-of-use patents: Protecting treatment methods, especially in orphan or rare disease areas.
Key Patent Trends
- Focus on selectivity to reduce side effects.
- Development of allosteric modulators for more precise control.
- Investments in drug delivery technologies, such as nanoparticles and targeted liposomes.
- Use of AI-driven drug discovery to identify novel transporter modulators.
Patent Expirations
Patents filed from 2010-2015 generally expire between 2030-2035, opening opportunities for generic development. Patent litigation often involves disputes over formulation or use patents, especially in the US and Europe.
Competitive Landscape
The field features both established pharmaceutical players and startups. Notable recent advances include:
- Electrophysiology-based drug screening platforms.
- Biotech developments in antibody-based transport modulators.
- Collaborations between biotech firms and academia for hit-to-lead optimization.
Regulatory Environment
Meeting regulatory requirements involves demonstrating drug selectivity, safety, and efficacy. The FDA and EMA provide expedited review pathways for breakthrough and orphan designations, which impact patent strategies. Data exclusivity periods complement patent rights in many jurisdictions.
Conclusion
Membrane transport modulators represent a mature yet actively innovating sector. Patent activity correlates with advancements in understanding transporter biology and drug design, with therapeutic expansion into neurodegeneration, oncology, and infectious diseases. Market growth is sustained by unmet medical needs and technological innovations.
Key Takeaways
- The global market for membrane transport modulators was approximately $15 billion in 2022, with a CAGR of about 6% projected through 2030.
- Major therapeutic areas are neurology, oncology, cardiology, and infectious diseases.
- Patent filings are concentrated in developed jurisdictions, with leading players like Novartis and Merck.
- Innovation focuses on selectivity, allosteric modulation, and drug delivery technologies.
- Expiring patents from 2010-2015 open opportunities for generics, amid ongoing IP disputes.
Frequently Asked Questions
1. Which therapeutic areas are seeing the most innovation in membrane transport modulators?
Neurological and oncological indications are primary drivers, with increasing interest in transporter-based strategies for drug resistance and precision targeting.
2. How does the patent landscape influence R&D strategies?
Patent filings guide development by defining competitive space. Firms focus on novel chemical entities, methods, and formulations to extend protection and circumvent existing patents.
3. What challenges exist in patenting membrane transport modulators?
Key challenges include demonstrating patentability over prior art, particularly for known transporter mechanisms, and navigating evolving regulatory requirements for safety and efficacy.
4. Are biosimilar or generic versions of these drugs expected soon?
Patents expiring between 2030-2035 could enable generics, but enforcement and licensing disputes may delay market entry.
5. What trends are emerging in the development of allosteric modulators?
Allosteric modulators offer improved selectivity, reducing side effects, and are gaining attention for neurodegenerative and psychiatric applications.
Citations
[1] MarketsandMarkets, "Membrane Transport Modulators Market," 2022.
More… ↓
